(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 2 394 636 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 72

(48) Corrigendum issued on:
18.01.2012 Bulletin 2012/03

(43) Date of publication:
14.12.2011 Bulletin 2011/50

(21) Application number: **10164362.5**

(22) Date of filing: **28.05.2010**

(51) Int Cl.:
A61K 9/00 *(2006.01)* ***A61K 47/14*** *(2006.01)*

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated Extension States:
BA ME RS

(71) Applicant: **Novagali Pharma S.A.**
91000 Evry (FR)

(72) Inventors:
- **Garrique, Jean-Sébastien**
  91370 Verrières le Buisson (FR)
- **Lallemand, Frédéric**
  94260 Fresnes (FR)
- **Heier, Jeffrey**
  Boston MA 02114 (US)

(74) Representative: **Icosa**
83 avenue Denfert-Rochereau
75014 Paris (FR)

(54) **Method for treating retinal conditions using an intraocular tamponade**

(57) Composition comprising at least one fatty acid glycerol ester for use in or after a vitrectomy procedure, said composition being bioresorbable, being injectable in the vitreous cavity, having a density below 1, more preferably comprised between 0.90 and 1, or a density above 1 more preferably between 1 and 1.5; having a surface tension of less than 50 dynes/cm more preferably ranging from 20 and 30 dynes/cm, being not susceptible to emulsify into droplets when injected; method for treating a retinal disorder involving the use of said composition.

EP 2 394 636 A8